StockData
TRex Bio, Inc. logo

TRex Bio, Inc. (TRXB) shareholders

TRXBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026
$10.00−0.77 (-7.15%)

Close on Nov 17, 2026Market cap $15.02MP/E –Yield –

Ownership

Who owns TRex Bio's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
3 buys · 0 sales
Net bought $3.80M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
ELI LILLY & Co5,480,87219.90%13D (active)Oct 13, 2026
Pfizer Inc. (13-5315170)1,965,0667.20%13G (passive)Oct 8, 2026
SV Biotech Crossover Opportunities Fund LP
Joint filing with Sv Bco I Gp Llp (7.00%)
1,920,6677.00%13D (active)Oct 8, 2026
Johnson & Johnson Innovation - JJDC, Inc.
Joint filing with Johnson & Johnson (5.30%)
1,475,3025.30%13G (passive)Oct 13, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Marion Johnston Erwin Jr.Chief Executive Officer, Director–Oct 8, 2026
Ariella KelmanChief Medical Officer–Oct 8, 2026
Laura BernerChief Operating Officer168,574Oct 8, 2026
Brandon HantsChief Financial Officer–Oct 8, 2026
Ali ZarrinChief Scientific Officer18,111Oct 8, 2026
Joel S. MarcusDirector41,871Oct 13, 2026
Peter HirthDirector38,202Oct 8, 2026
Carol Giltner GallagherDirector251,471Oct 8, 2026
Michael Jay RossDirector–Oct 8, 2026
Travis Alan CoyDirector–Oct 8, 2026
Julie Ann GilmoreDirector–Oct 8, 2026
Alexandria Venture Investments, LLC10% owner1,346,501Oct 15, 2026
SV Life Sciences Fund VI (GP), L.P.10% owner–Oct 13, 2026
Svlsf Vi, Llc10% owner3,011,818Oct 13, 2026
SV Life Sciences Fund VI, L.P.10% owner–Oct 13, 2026
LILLY & Co ELI10% owner5,480,872Oct 8, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Alexandria Venture Investments, LLC
10% owner
Oct 13, 2026Buy+178,571$14.00$2.50M1,346,501
Alexandria Venture Investments, LLC
10% owner
Oct 13, 2026Conversion+1,167,930––1,167,930
Svlsf Vi, Llc
10% owner
Oct 13, 2026Conversion+669,939––669,939
Svlsf Vi, Llc
10% owner
Oct 13, 2026Conversion+16,277––77,525
Svlsf Vi, Llc
10% owner
Oct 13, 2026Conversion+53,892––61,248
Svlsf Vi, Llc
10% owner
Oct 13, 2026Conversion+475,411––2,264,354
Svlsf Vi, Llc
10% owner
Oct 13, 2026Conversion+1,574,074––1,788,943
Joel S. Marcus
Director
Oct 13, 2026Conversion+41,871––41,871
Svlsf Vi, Llc
10% owner
Oct 8, 2026Buy+3,074$14.00$43.04K7,356
Svlsf Vi, Llc
10% owner
Oct 8, 2026Buy+89,783$14.00$1.26M214,869

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
10.47%
0M shares short
Days to cover
2.3
At 0M shares a day
Change since last report
-19.6%
From 0M shares
Short volume, 20 days
57.8%
Of volume reported to FINRA

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of TRex Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 144,681 shares on Oct 13, 2026 over the last 90 days.

See a number that looks wrong?